ASC4FIRST Trial & Asciminib New FDA Approval: Evaluating Asciminib in First-Line CML Treatment

Video content above is prompted by the following:

• Can you tell us about the trial design, key end points, and your impressions of the data?
• With the recent FDA approval of asciminib in the first-line (1L) setting, how will you incorporate this into your practice?
  • Are there particular patients whom you would consider for asciminib vs first- or second-generation tyrosine kinase inhibitors?
• Please share any anticipated similarities or differences in your clinical practice now that asciminib has received FDA approval in the 1L setting.